TY - JOUR
T1 - Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients
AU - Hamaad, A
AU - Kaeng Lee, W
AU - Lip, Gregory
AU - Macfadyen, Robert
PY - 2006/10/1
Y1 - 2006/10/1
N2 - OBJECTIVE: To determine the effects of n3-PUFA supplementation, in the dose used in the GISSI-Prevenzione study, on indices of heart rate variability (HRV) in patients following myocardial infarction (AMI). MATERIALS AND METHODS: Open label randomised single blind controlled trial. Thirty eight patients post AMI, stable on standard secondary prevention drug therapy were single blind randomised to receive either Omacor 1 g/day (n = 21) or usual care (n = 17). HRV indices (time and frequency-domain) were measured at baseline and following 3 months of treatment. RESULTS: At baseline there were no significant differences in clinical, biochemical or HRV indices between patient groups. After 3 months therapy there were no observed changes in measured HRV indices in either the Omacor supplemented or 'usual care' groups. CONCLUSIONS: Three month supplementation of omega 3 PUFA (Omacor) 1 g/day has no effect on HRV is patients post AMI.
AB - OBJECTIVE: To determine the effects of n3-PUFA supplementation, in the dose used in the GISSI-Prevenzione study, on indices of heart rate variability (HRV) in patients following myocardial infarction (AMI). MATERIALS AND METHODS: Open label randomised single blind controlled trial. Thirty eight patients post AMI, stable on standard secondary prevention drug therapy were single blind randomised to receive either Omacor 1 g/day (n = 21) or usual care (n = 17). HRV indices (time and frequency-domain) were measured at baseline and following 3 months of treatment. RESULTS: At baseline there were no significant differences in clinical, biochemical or HRV indices between patient groups. After 3 months therapy there were no observed changes in measured HRV indices in either the Omacor supplemented or 'usual care' groups. CONCLUSIONS: Three month supplementation of omega 3 PUFA (Omacor) 1 g/day has no effect on HRV is patients post AMI.
U2 - 10.1007/s10557-006-0295-z
DO - 10.1007/s10557-006-0295-z
M3 - Article
C2 - 17089085
SN - 1573-7241
VL - 20
SP - 359
EP - 364
JO - Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy
JF - Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy
IS - 5
ER -